Advanced Filters
noise
Found 1,889 clinical trials
F Feng-Ming (Spring) KONG, Professor

RAPART in Locally Advanced Non-small Cell Lung Cancer Patients

This is a Phase II/III randomized clinical trial of Radiosensitivity-Assisted Personalized Adaptive Radiotherapy Technology (RAPART) in locally advanced non-small cell lung cancer patients. The main objective is to test the overall improvement of overall survival (OS), progression free survival (PFS), and local progression free survival (LPFS) of unresectable stage III …

18 years of age All Phase N/A

Epidemiology of Abdominal Aortic Aneurysm With Concomitant Primary Lung Cancer

Retrospective clinical case studies in recent years have shown that most cases of lung cancer and abdominal aortic aneurysm (AAA) are detected at the same time and that there is a wide variation in the prevalence of AAA in patients with primary lung cancer reported in the literature, with some …

20 - 90 years of age All Phase N/A

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.

18 years of age All Phase 1/2
Y Yongchang Zhang, MD

Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer

Although several clinical trials provide evidence for efficacy benefit for Checkpoint Inhibitors plus chemotherapy for lung cancer. However, there was rare evidence for clinical evidence in Hunan province.

18 years of age All Phase N/A
D Dong-Xin Wang, MD, PHD

Intraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery

Surgery is the front-line therapy for non-small cell lung cancer (NSCLC) but postoperative complications remains high and patients' long-term outcome is still challenging. In addition to surgery, anesthetic management particularly intraoperative blood pressure management and use of dexamethasone may affect patients' early and long-term outcomes after surgery for NSCLC. This …

50 - 90 years of age All Phase N/A

Prospective Multicentre Study for the Application of Telomere Measurement Technology as a Tool for Lung Cancer Diagnosis

This research is a clinical performance study of in vitro diagnostic device (IVD), a prospective, multicentre, open-label, case-control clinical investigation aimed at constructing a predictive model that allows results to be classified as positive or negative in relation to the probability of having lung cancer.

45 years of age All Phase N/A
L Long Hao, MD

Effects of Digital Therapeutic in Whole Process Management of Lung Cancer

This trial will randomize patients into two groups, the treatment group will use the digital therapeutic application named 'UHealth' for the whole process management and the control group will use regular follow-up. The trial aims to look into the difference between quality of life, anxiety/depression index, emergency treatment times, hospital …

18 - 70 years of age All Phase 3

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine, standard-of-care screening Low-Dose Computed Tomography (LDCT).

50 years of age All Phase N/A

Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer

This is a multicenter,randomized, open label, active-controlled, parallel-group study comparing efficacy and safety of LY01610(Irinotecan hydrochloride liposome Injection) and Topotecan in Patients with Recurrent Small Cell Lung Cancer (SCLC)

18 years of age All Phase 3

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combination with Durvalumab or Rilvegostomig and single agent platinum chemotherapy …

18 - 95 years of age All Phase 2

Simplify language using AI